Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 3/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | HTR2B | P41595 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 2/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | PTPRC | P08575 | 3/20 | 0.47 |
| ▸ | BCHE | P06276 | 1/20 | 0.47 |
| ▸ | ACHE | P22303 | 1/20 | 0.47 |
| ▸ | CES1 | P23141 | 1/20 | 0.47 |
| ▸ | S100A4 | P26447 | 1/20 | 0.47 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9148185 | 0.76 | HTR2A (0.52) | KDM4ELMNAMAPTHTR2BGAA | |
| SCHEMBL10840857 | 0.75 | TSHR (0.59) | KDM4ELMNAMAPTTP53GAA | |
| SCHEMBL29525131 | 0.72 | TSHR (0.59) | KDM4ELMNAMAPTTP53GAA | |
| SCHEMBL4573093 | 0.72 | MEN1 (0.68) | KDM4ELMNAMAPTTP53CYP1A2 | |
| SCHEMBL30317990 | 0.72 | TSHR (0.59) | KDM4ELMNAMAPTTP53GAA | |
| SCHEMBL14940009 | 0.72 | MAPT (0.61) | KDM4ELMNAMAPTTP53CYP1A2 | |
| SCHEMBL14939315 | 0.72 | MEN1 (0.63) | KDM4ELMNAMAPTTP53CYP1A2 | |
| SCHEMBL8957963 | 0.72 | MEN1 (0.63) | KDM4ELMNAMAPTTP53CYP1A2 | |
| SCHEMBL14939598 | 0.72 | RAB9A (0.63) | KDM4ELMNAMAPTTP53CYP1A2 | |
| SCHEMBL10046438 | 0.72 | TSHR (0.59) | KDM4ELMNAMAPTTP53GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1501822-B1 | PHTHALAZINONE DERIVATIVES | KUDOS PHARM LTD (GB) | 2010-12-15 | — | — | EP | disclosed |
| US-7196085-B2 | Phthalazinone derivatives | KUDOS PHARMACEUTICALS LIMITED (GB) | 2007-03-27 | — | — | US | disclosed |
| US-7196085-B2 | Phthalazinone derivatives | KUDOS PHARMACEUTICALS LIMITED (GB) | 2007-03-27 | — | — | US | disclosed |
| US-7196085-B2 | Phthalazinone derivatives | KUDOS PHARMACEUTICALS LIMITED (GB) | 2007-03-27 | — | — | US | disclosed |
| EP-1501822-A1 | PHTHALAZINONE DERIVATIVES | Kudos Pharmaceuticals Limited (GB) | 2005-02-02 | — | — | EP | disclosed |
| US-20040023968-A1 | Phthalazinone derivatives, and their use as pharmaceuticals. In particular, the present as enzyme inhibitors | KUDOS PHARMACEUTICALS LIMITED (GB) | 2004-02-05 | — | — | US | disclosed |
| WO-2003093261-A1 | PHTHALAZINONE DERIVATIVES | KUDOS PHARMACEUTICALS LIMITED (GB) | 2003-11-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040023968-A1 | Phthalazinone derivatives, and their use as pharmaceuticals. In particular, the present as enzyme inhibitors | PARP1, PARP2, PARP15 | KDM4E 707/4885LMNA 233/4885MAPT 505/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.